Koshi Akahane

1.4k total citations
63 papers, 658 citations indexed

About

Koshi Akahane is a scholar working on Hematology, Molecular Biology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Koshi Akahane has authored 63 papers receiving a total of 658 indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Hematology, 20 papers in Molecular Biology and 20 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Koshi Akahane's work include Chronic Myeloid Leukemia Treatments (25 papers), Acute Lymphoblastic Leukemia research (20 papers) and Chronic Lymphocytic Leukemia Research (9 papers). Koshi Akahane is often cited by papers focused on Chronic Myeloid Leukemia Treatments (25 papers), Acute Lymphoblastic Leukemia research (20 papers) and Chronic Lymphocytic Leukemia Research (9 papers). Koshi Akahane collaborates with scholars based in Japan, United States and Singapore. Koshi Akahane's co-authors include Takeshi Inukai, Kumiko Goi, A. Thomas Look, Takaomi Sanda, Keiko Kagami, Kanji Sugita, Hiroaki Goto, David M. Weinstock, Marc R. Mansour and Minori Tamai and has published in prestigious journals such as Nature Communications, Blood and Cancer Research.

In The Last Decade

Koshi Akahane

55 papers receiving 646 citations

Peers

Koshi Akahane

ONCOL

HEMAT

PHEOH

IMMUN

Simon Bomken United Kingdom

Natalia Liem Singapore

Marta Sánchez-Martín United States

David S. Chervinsky United States

Richard Smykla United States

Heather Bendall United States

Justin M. Watts United States

Antonia Rodríguez Spain

Anand Jillella United States

Rhonda E. Ries United States

Simon Bomken United Kingdom

Koshi Akahane

376 ×1.2

366 ×1.7

ONCOL

234 ×1.3

HEMAT

202 ×1.5

PHEOH

146 ×1.5

IMMUN

Citations per year, relative to Koshi Akahane Koshi Akahane (= 1×) peers Simon Bomken

Countries citing papers authored by Koshi Akahane

Since Specialization

Citations

This map shows the geographic impact of Koshi Akahane's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Koshi Akahane with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Koshi Akahane more than expected).

Fields of papers citing papers by Koshi Akahane

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Koshi Akahane. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Koshi Akahane. The network helps show where Koshi Akahane may publish in the future.

Co-authorship network of co-authors of Koshi Akahane

This figure shows the co-authorship network connecting the top 25 collaborators of Koshi Akahane. A scholar is included among the top collaborators of Koshi Akahane based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Koshi Akahane. Koshi Akahane is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tamai, Minori, Atsushi Watanabe, Koshi Akahane, et al.. (2025). A characteristic gene expression profile regulated by ACIN1::NUTM1 fusion in a newly identified infant leukaemic cell line and an ACIN1 :: NUTM1 ‐inducible model. British Journal of Haematology. 207(5). 1842–1854.

Watanabe, Atsushi, et al.. (2025). Multifocal osteonecrosis as well as repeated bone fractures due to osteoporosis in a prepubertal ALL case. Pediatrics International. 67(1). e70087–e70087.

Tamai, Minori, Keiko Kagami, Koshi Akahane, et al.. (2025). Utility of a Large Series of B‐Cell Precursor Acute Lymphoblastic Leukemia Cell Lines as a Model System. Cancer Medicine. 14(5). e70736–e70736. 1 indexed citations

Nguyen, Thao, Tomomi Aida, Yuka Iijima‐Yamashita, et al.. (2024). Application of prime editing system to introduce TP53 R248Q hotspot mutation in acute lymphoblastic leukemia cell line. Cancer Science. 115(6). 1924–1935. 3 indexed citations

Chang, Yunchao, Gisele Nishiguchi, Qingsong Gao, et al.. (2023). The orally bioavailable GSPT1/2 degrader SJ6986 exhibits in vivo efficacy in acute lymphoblastic leukemia. Blood. 142(7). 629–642. 19 indexed citations

Watanabe, Atsushi, Kunio Miyake, Minori Tamai, et al.. (2023). Utility of ASNS gene methylation evaluated with the HPLC method as a pharmacogenomic biomarker to predict asparaginase sensitivity in BCP-ALL. Epigenetics. 18(1). 2268814–2268814. 2 indexed citations

Ishii, Yuko, Jinhua Piao, Mitsuko Masutani, et al.. (2023). Targeting Poly(ADP)ribose polymerase in BCR/ABL1-positive cells. Scientific Reports. 13(1). 7588–7588. 2 indexed citations

Tamai, Minori, Koshi Akahane, Thao Nguyen, et al.. (2022). Glucocorticoid receptor gene mutations confer glucocorticoid resistance in B-cell precursor acute lymphoblastic leukemia. The Journal of Steroid Biochemistry and Molecular Biology. 218. 106068–106068. 7 indexed citations

Tamai, Minori, Shinichi Fujisawa, Thao Nguyen, et al.. (2022). Creation of Philadelphia chromosome by CRISPR/Cas9-mediated double cleavages on BCR and ABL1 genes as a model for initial event in leukemogenesis. Cancer Gene Therapy. 30(1). 38–50. 2 indexed citations

10.

Tsuzuki, Shinobu, Takahiko Yasuda, Hiroaki Goto, et al.. (2022). BCL6 inhibition ameliorates resistance to ruxolitinib in <i>CRLF2</i>-rearranged acute lymphoblastic leukemia. Haematologica. 108(2). 394–408. 8 indexed citations

11.

Sasaki, Kensuke, Takuji Yamauchi, Yuichiro Semba, et al.. (2021). Genome-wide CRISPR-Cas9 screen identifies rationally designed combination therapies for CRLF2- rearranged Ph-like ALL. Blood. 139(5). 748–760. 13 indexed citations

12.

Yoshioka, Makoto, Kuniaki Tanaka, Shyh‐Ming Yang, et al.. (2021). CN470 is a BET/CBP/p300 multi-bromodomain inhibitor and has an anti-tumor activity against MLL-rearranged acute lymphoblastic leukemia. Biochemical and Biophysical Research Communications. 590. 49–54. 11 indexed citations

13.

Shindo, Takero, Kaori Nakayama‐Hosoya, Koshi Akahane, et al.. (2021). KIR3DL1 Allotype-Dependent Modulation of NK Cell Immunity against Chronic Myeloid Leukemia. ImmunoHorizons. 5(8). 687–702. 4 indexed citations

14.

Watanabe, Atsushi, Kunio Miyake, Koshi Akahane, et al.. (2021). Epigenetic Modification of Death Receptor Genes for TRAIL and TRAIL Resistance in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia. Genes. 12(6). 864–864. 6 indexed citations

15.

Zhao, Yaqi, Ibrahim Aldoss, Chunxu Qu, et al.. (2020). Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL. Blood. 137(4). 471–484. 77 indexed citations

16.

Kumar, Rahul, Raquel Pereira, Valentina R. Minciacchi, et al.. (2020). Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia. Leukemia. 34(8). 2087–2101. 29 indexed citations

17.

Wang, Lu, Tze King Tan, Adam D. Durbin, et al.. (2019). ASCL1 is a MYCN- and LMO1-dependent member of the adrenergic neuroblastoma core regulatory circuitry. Nature Communications. 10(1). 5622–5622. 54 indexed citations

18.

Nemoto, Atsushi, Satoshi Saida, Itaru Kato, et al.. (2015). Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome–Positive Lymphoid Leukemia. Molecular Cancer Therapeutics. 15(1). 94–105. 20 indexed citations

19.

Goi, Kumiko, Takeshi Inukai, Hiroki Sato, et al.. (2007). Fms-like Tyrosine Kinase 3 Ligand Stimulation Induces MLL -Rearranged Leukemia Cells into Quiescence Resistant to Antileukemic Agents. Cancer Research. 67(20). 9852–9861. 24 indexed citations

20.

Nagata, A., Koshi Akahane, Hideto Yonekura, et al.. (1985). [Clinical significance of the fecal chymotrypsin test in chronic pancreatitis--comparative study of its value with the pancreozymin-secretin test, PFD test, and endoscopic retrograde pancreatography].. PubMed. 82(12). 2964–72.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact